These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 30986706)

  • 1. Melanoma during fingolimod treatment for multiple sclerosis.
    Velter C; Thomas M; Cavalcanti A; Bastien M; Chochon F; Lubetzki C; Routier E; Robert C
    Eur J Cancer; 2019 May; 113():75-77. PubMed ID: 30986706
    [No Abstract]   [Full Text] [Related]  

  • 2. Multiple Sclerosis Treatment and Melanoma Development.
    Carbone ML; Lacal PM; Messinese S; De Giglio L; Pozzilli C; Persechino S; Mazzanti C; Failla CM; Pagnanelli G
    Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32331328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational study.
    Barbin L; Rousseau C; Jousset N; Casey R; Debouverie M; Vukusic S; De Sèze J; Brassat D; Wiertlewski S; Brochet B; Pelletier J; Vermersch P; Edan G; Lebrun-Frenay C; Clavelou P; Thouvenot E; Camdessanché JP; Tourbah A; Stankoff B; Al Khedr A; Cabre P; Papeix C; Berger E; Heinzlef O; Debroucker T; Moreau T; Gout O; Bourre B; Créange A; Labauge P; Magy L; Defer G; Foucher Y; Laplaud DA;
    Neurology; 2016 Feb; 86(8):771-8. PubMed ID: 26826205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Five cases of malignant melanoma during fingolimod treatment in Dutch patients with MS.
    Killestein J; Leurs CE; Hoogervorst ELJ; van Eijk J; Mostert JP; van den Eertwegh AJM; Uitdehaag BMJ
    Neurology; 2017 Aug; 89(9):970-972. PubMed ID: 28768850
    [No Abstract]   [Full Text] [Related]  

  • 5. Plasma protein profiling reveals candidate biomarkers for multiple sclerosis treatment.
    Bedri SK; Nilsson OB; Fink K; Månberg A; Hamsten C; Ayoglu B; Manouchehrinia A; Nilsson P; Olsson T; Hillert J; Grönlund H; Glaser A
    PLoS One; 2019; 14(5):e0217208. PubMed ID: 31141529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dengue fever in patients with multiple sclerosis taking fingolimod or natalizumab.
    Fragoso YD; Gama PDD; Gomes S; Khouri JMN; Matta APDC; Fernanda Mendes M; Stella CRAV
    Mult Scler Relat Disord; 2016 Mar; 6():64-65. PubMed ID: 27063625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis.
    Iaffaldano P; Lucisano G; Pozzilli C; Brescia Morra V; Ghezzi A; Millefiorini E; Patti F; Lugaresi A; Zimatore GB; Marrosu MG; Amato MP; Bertolotto A; Bergamaschi R; Granella F; Coniglio G; Tedeschi G; Sola P; Lus G; Ferrò MT; Iuliano G; Corea F; Protti A; Cavalla P; Guareschi A; Rodegher M; Paolicelli D; Tortorella C; Lepore V; Prosperini L; Saccà F; Baroncini D; Comi G; Trojano M;
    Brain; 2015 Nov; 138(Pt 11):3275-86. PubMed ID: 26362907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple sclerosis treatment effects on plasma cytokine receptor levels.
    Bedri SK; Fink K; Manouchehrinia A; Lundström W; Kockum I; Olsson T; Hillert J; Glaser A
    Clin Immunol; 2018 Feb; 187():15-25. PubMed ID: 28941836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies.
    Baroncini D; Ghezzi A; Annovazzi PO; Colombo B; Martinelli V; Minonzio G; Moiola L; Rodegher M; Zaffaroni M; Comi G
    Mult Scler; 2016 Sep; 22(10):1315-26. PubMed ID: 27230789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fingolimod treatment after natalizumab-related progressive multifocal leukoencephalopathy: three new cases.
    Peaureaux D; Pignolet B; Biotti D; Bucciarelli F; Gaina J; Bucur C; Clanet M; Martin-Blondel G; Brassat D
    Mult Scler; 2015 Apr; 21(5):671-2. PubMed ID: 25305251
    [No Abstract]   [Full Text] [Related]  

  • 11. A comparison of multiple sclerosis clinical disease activity between patients treated with natalizumab and fingolimod.
    Koch-Henriksen N; Magyari M; Sellebjerg F; Soelberg Sørensen P
    Mult Scler; 2017 Feb; 23(2):234-241. PubMed ID: 27055806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing-remitting multiple sclerosis.
    Lorscheider J; Benkert P; Lienert C; Hänni P; Derfuss T; Kuhle J; Kappos L; Yaldizli Ö
    Mult Scler; 2018 May; 24(6):777-785. PubMed ID: 29685071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel Agents for Relapsing Forms of Multiple Sclerosis.
    Straus Farber R; Harel A; Lublin F
    Annu Rev Med; 2016; 67():309-21. PubMed ID: 26394285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systematic literature review and network meta-analysis in highly active relapsing-remitting multiple sclerosis and rapidly evolving severe multiple sclerosis.
    Huisman E; Papadimitropoulou K; Jarrett J; Bending M; Firth Z; Allen F; Adlard N
    BMJ Open; 2017 Mar; 7(3):e013430. PubMed ID: 28283486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Shortening the washout to 4 weeks when switching from natalizumab to fingolimod and risk of disease reactivation in multiple sclerosis.
    Naegelin Y; Rasenack M; Andelova M; Von Felten S; Fischer-Barnicol B; Amann M; Mehling M; Kappos L; Sprenger T; Derfuss T
    Mult Scler Relat Disord; 2018 Oct; 25():14-20. PubMed ID: 30014876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and Efficacy of Fingolimod and Natalizumab in Multiple Sclerosis After the Failure of First-Line Therapy: Single Center Experience Based on the Treatment of Forty-Four Patients.
    Puz P; Lasek-Bal A
    Med Sci Monit; 2016 Nov; 22():4277-4282. PubMed ID: 27829656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fingolimod effects on left ventricular function in multiple sclerosis.
    Racca V; Di Rienzo M; Cavarretta R; Toccafondi A; Vaini E; Ferratini M; Rovaris M
    Mult Scler; 2016 Feb; 22(2):201-11. PubMed ID: 26041795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome with intravenous immunoglobulin in a patient with multiple sclerosis treated with fingolimod after discontinuation of natalizumab.
    Calic Z; Cappelen-Smith C; Hodgkinson SJ; McDougall A; Cuganesan R; Brew BJ
    J Clin Neurosci; 2015 Mar; 22(3):598-600. PubMed ID: 25523125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative analysis of first-year fingolimod and natalizumab drug discontinuation among Swedish patients with multiple sclerosis.
    Frisell T; Forsberg L; Nordin N; Kiesel C; Alfredsson L; Askling J; Hillert J; Olsson T; Piehl F
    Mult Scler; 2016 Jan; 22(1):85-93. PubMed ID: 25921036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Merkel cell carcinoma with fingolimod treatment for multiple sclerosis: A case report.
    Mahajan KR; Ko JS; Tetzlaff MT; Hudgens CW; Billings SD; Cohen JA
    Mult Scler Relat Disord; 2017 Oct; 17():12-14. PubMed ID: 29055440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.